Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in Switzerland
As an adjuvant treatment of RCC post-nephrectomy, pembrolizumab was found to be cost-effective versus observation in Switzerland at a WTP threshold of CHF 100,000/QALY. Policy makers should consider pembrolizumab as an adjuvant treatment for patients with RCC post-nephrectomy when making decisions regarding resource allocation.
Authors
- Judith E. Lupatsch (ORCID: https://orcid.org/0000-0002-0337-1291)
- Michael Flori
- Nadine Schur (ORCID: https://orcid.org/0000-0002-8313-2820)
- Andrea Favre-Bulle
- Ying Xiao (ORCID: https://orcid.org/0000-0002-6855-0207)
Institutions
- University of Basel (CH)
- MSD (UK) Limited (United Kingdom) (GB)
- MSD (Switzerland) (CH)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1080/13696998.2024.2417523
- Citations
- 3
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.39